Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals : Treats First Patient in Phase 2 Study of Stroke Drug; Shares Fall 3%

06/07/2021 | 01:58am EDT


© MT Newswires 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
06/07CLINUVEL PHARMACEUTICALS : Treats First Patient in Phase 2 Study of Stroke Drug;..
MT
06/06CLINUVEL PHARMACEUTICALS : Media release - First stroke patient with afamelanoti..
PU
06/06CLINUVEL PHARMACEUTICALS : First stroke patient treated with afamelanotide
PU
06/06Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with ..
CI
06/03CLINUVEL PHARMACEUTICALS : Presentation to Jefferies Healthcare Conference
PU
06/02CLINUVEL PHARMACEUTICALS : Newsletter 3 - June 2021
PU
04/28CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
04/11CLINUVEL PHARMACEUTICALS : Strategic Update II - April 2021
PU
03/31CLINUVEL PHARMACEUTICALS : Newsletter II - April 2021
PU
03/24CLINUVEL PHARMACEUTICALS : SCENESSE to be assessed in xeroderma pigmentosum vari..
PU
More news
Financials
Sales 2021 43,7 M 32,2 M 32,2 M
Net income 2021 18,5 M 13,6 M 13,6 M
Net cash 2021 83,2 M 61,3 M 61,3 M
P/E ratio 2021 81,8x
Yield 2021 0,09%
Capitalization 1 468 M 1 082 M 1 081 M
EV / Sales 2021 31,7x
EV / Sales 2022 22,9x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 29,72 AUD
Average target price 30,54 AUD
Spread / Average Target 2,76%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors